



FOR IMMEDIATE RELEASE

CONTACT: Tammi L. Thomas
tammi@umbc.edu
410-455-6784

Two More Life Science Companies Embrace UMBC

Tradezyme and Biomedica Management Corporation Join techcenter@UMBC Incubator Program

BALTIMORE, MD (January 19, 2007) – The techcenter@UMBC welcomes Tradezyme, LLC and Biomedica Management Corporation, both privately held biotech companies.

Tradezyme, formerly known as GeneTrade, has a rich connection with Greater Baltimore. The founders, Paul M. Kim and Daniel S. Higginson, are Johns Hopkins University medical students. They won the Greater Baltimore Technology Council's 2005 MoshPit Business Plan competition, which included \$15,000 and free office space at the Emerging Tech Center in Baltimore. The company received \$75,000 in funding from the Maryland Technology Development Corporation's (TEDCO) Maryland Technology Transfer Fund (MTTF) last year.

Tradezyme is developing a registry and exchange for plasmids which are specially designed pieces of DNA used in scientific research. Tradezyme will also provide a gene-cloning service to biotech companies and academic labs.

"UMBC's biotech cluster is growing stronger, with such companies as In Vitro Technologies, Cognate Bioservices, Lentigen, Profectus Biosciences, and Traxion Therapeutics among the group," says techcenter@UMBC Director Walt Schulz. "We are delighted to welcome Tradezyme and Biomedica into the fold."

Biomedica Management Corporation assists small businesses to move their research innovations into the commercialization path. Biomedica focuses on the Small Business Innovation Research (SBIR) program and other agencies under the auspices of federal Public Health Service. Biomedica helps scientific investigators obtain and manage funding, pursue patents, and market the commercialization. Biomedica is moving its laboratory facilities from Kalamazoo, MI to the techcenter@UMBC in Catonsville, Maryland.

Biomedica recently received \$75,000 in funding from TEDCO's MTTF program to improve the treatment of combat-related injuries which are the major cause of death among wounded soldiers.

"techcenter@UMBC is an outstanding place to grow our biotech company," says George Falus, CEO of Biomedica. "Its wealth of strategic alliances, outstanding support services, and proximity to federal agencies and world-class research institutions are sure to accelerate our successful business development."

Biomedica is working with UMBC chemistry professor James C. Fishbein on the development of wound healing and anti-inflammatory compounds that can prevent serious organ damage resulting from hemorrhage, heart and liver disease, and transplantation.

About techcenter@UMBC: UMBC's technology incubator, founded in 1989, was expanded in 1996 when UMBC purchased the 30-acre five-building Lockheed Martin Research Lab facility site and renamed it techcenter@UMBC. techcenter@UMBC is home to approximately 30 early stage and mature companies. For more information about the techcenter@UMBC visit the website at www.umbc.edu/techcenter.

Phase II is bwtech@UMBC, a 41-acre research and technology community. bwtech@UMBC has a total development capacity of up to 350,000 square feet of office and laboratory space. The park will ultimately comprise five new state-of-the-art buildings occupied by research and technology firms. Both projects combined have over 40 tenants representing diverse technologies ranging from mechanical engineering to pharmaceutical research, from environmental sampling to biotechnology. For more information about the bwtech@UMBC Research and Technology Park visit the website at www.bwtechumbc.com.

###